Galera Therapeutics, Inc.

GRTXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1563577

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Research and Development Expense	$24.1M	$31.0M	$52.4M	$54.8M	$42.3M
Operating Income (Loss)	-$49.3M	-$51.2M	-$73.4M	-$70.6M	-$50.7M
Interest Expense	$11.4M	$11.6M	$7.2M	$4.9M	$3.0M
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$59.1M	-$62.3M	-$80.5M	-$74.2M	-$51.9M
Income Tax Expense (Benefit)	$0.00	$70.0K	$0.00	-$16.0K	-$9.0K
Net Income (Loss) Attributable to Parent	-$59.1M	-$62.2M	-$80.5M	-$74.2M	-$51.9M
Earnings Per Share, Basic	-$1.33	—	—	—	—
Earnings Per Share, Diluted	-$1.33	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$26.1M	$44.0M	$83.3M	$84.1M	$123.4M
Assets, Current	$21.6M	$38.5M	$77.4M	$77.9M	$117.6M
Cash and Cash Equivalents, at Carrying Value	$18.3M	$4.3M	$19.9M	$15.9M	$18.4M
Liabilities	$157.3M	$153.2M	$141.3M	$78.0M	$53.8M
Liabilities, Current	$5.0M	$13.4M	$12.9M	$14.0M	$9.7M
Accounts Payable, Current	$1.4M	$3.6M	$5.0M	$5.1M	$3.9M
Stockholders' Equity Attributable to Parent	-$109.2M	-$58.0M	$6.1M	$69.6M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$44.8M	-$43.4M	-$68.0M	-$59.5M	-$46.7M
Net Cash Provided by (Used in) Investing Activities	$27.3M	$24.0M	$5.2M	$36.5M	-$27.8M
Net Cash Provided by (Used in) Financing Activities	$31.5M	$3.9M	$66.7M	$20.5M	$78.0M
Payments to Acquire Property, Plant, and Equipment	$59.0K	$25.0K	$283.0K	$457.0K	$633.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)